The number of fractures occurring in patients was summarised in 6-month intervals. A logistic regression
with repeated measures was used to assess the change in number of patients with one or more fractures over time [19, 20]. In contrast to survival analysis, where the hazard of the first Brigatinib fracture is presented, logistic regression is an analysis of the odds of fracture (e.g., ratio of patients who fracture versus patients who do not fracture). Patients were included in the model at all observed intervals, regardless of whether or not they fractured during a previous interval. The repeated observations of each patient BMN 673 price were assumed to be related but no further assumptions were made about the relationship. Unadjusted and adjusted models were performed including age, prior bisphosphonate use and a history of fracture in the last 12 months before starting teriparatide. Contrasts were made between the odds of fracture in the first 6 months of treatment (0 to <6 months) and each subsequent
6-month period. Fracture modelling was repeated for all vertebral, all non-vertebral and main non-vertebral (forearm/wrist, hip, humerus, leg and ribs) fractures. Back pain VAS changes from baseline were analysed using a mixed model for repeated measures (MMRM) adjusting for back pain VAS at baseline, number of previous fractures, age, diagnosis of rheumatoid arthritis, duration of prior bisphosphonate therapy, and a history of fracture in the 12 months before entering the study. The p values represent the unique influence of the corresponding factor after adjustment for all other factors in the model. The number of patients reporting C646 mw an improvement or worsening in the severity, frequency, limitation of activities and number of days in bed (≤2 days: no
change) due to back pain was analysed using the sign test. Results Patient disposition and characteristics Figure 1 summarises the patient flow through the study and the number of patients with observations at each visit for the total study cohort and the post-teriparatide cohort. Overall, 1,581 patients were analysed at baseline and returned for at least one post-baseline visit; this constitutes the total study cohort. As this was an observational study with data collection occurring within the normal course of Rutecarpine clinical care, some patients missed subsequent targeted data collection visits (as detailed in Fig. 1) but returned for a later visit. Moreover, at each time point, no further data were available for some patients (i.e., these patients discontinued or were lost to follow-up). The baseline characteristics of the total study cohort are summarised in Table 1. Fig. 1 Study flow and disposition of patients in the total study cohort and post-teriparatide cohort Table 1 Baseline characteristics of total study cohort (n = 1,581) Characteristic Total study cohort Caucasian,% 99.2 Age, years 71.0 (8.4) Years since menopause 24.8 (9.